Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
---|---|
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00890643 |
In this study, the investigators are looking at how PTSD affects things such as memory, attention, reaction to sounds, eye movements, and heart rate. The investigators are also studying whether a medication called prazosin has an effect on these things.
Condition | Intervention |
---|---|
Posttraumatic Stress Disorder |
Drug: prazosin hydrochloride Drug: placebo |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Efficacy Study |
Official Title: | Effect of Prazosin on Neurophysiologic Responses and Cognitive Performance in PTSD |
Estimated Enrollment: | 120 |
Study Start Date: | June 2009 |
Estimated Study Completion Date: | September 2011 |
Estimated Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Persons with PTSD
|
Drug: prazosin hydrochloride
prazosin 1-20 mg/day in divided doses
|
2: Placebo Comparator
Persons with PTSD
|
Drug: placebo
placebo
|
Converging lines of evidence suggest that central noradrenergic function is perturbed in PTSD. Placebo-controlled trials demonstrate that the centrally acting alpha-1 antagonist prazosin is clinically effective for several core symptoms of PTSD in combat veterans. However, no detailed assessment of the impact of prazosin on human neurophysiology and cognition have been conducted. Our hypotheses are based on studies that demonstrate (1) the importance of central adrenergic receptors in regulating fundamental neurophysiologic and cognitive functions, (2) the alteration of these functions in PTSD, and (3) the efficacy of prazosin in improving the clinical symptoms of PTSD. The primary objective of this study is to measure the subtle neurocognitive and neurophysiologic effects on prazosin in combat veterans with PTSD.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Dorcas J Dobie, MD | (206) 764-2007 | dorcas.dobie@va.gov |
Contact: Denise Pritzl, MSW | (206) 277-4731 | denise.pritzl@va.gov |
United States, Washington | |
VA Puget Sound Health Care System | |
Seattle, Washington, United States, 98109 |
Principal Investigator: | Dorcas J. Dobie, MD | VA Puget Sound Health Care System |
Responsible Party: | Department of Veterans Affairs ( Dobie, Dorcas - Principal Investigator ) |
Study ID Numbers: | MHBA-018-08S |
Study First Received: | April 28, 2009 |
Last Updated: | April 29, 2009 |
ClinicalTrials.gov Identifier: | NCT00890643 History of Changes |
Health Authority: | United States: Federal Government |
Stress disorders, post-traumatic Combat Disorders prazosin cognition neurophysiology |
Neurotransmitter Agents Adrenergic Agents Stress Adrenergic alpha-Antagonists Cardiovascular Agents Antihypertensive Agents Stress Disorders, Traumatic |
Combat Disorders Anxiety Disorders Mental Disorders Prazosin Stress Disorders, Post-Traumatic Adrenergic Antagonists |
Neurotransmitter Agents Disease Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Stress Cardiovascular Agents Adrenergic alpha-Antagonists Antihypertensive Agents |
Pharmacologic Actions Stress Disorders, Traumatic Pathologic Processes Anxiety Disorders Mental Disorders Prazosin Therapeutic Uses Stress Disorders, Post-Traumatic Adrenergic Antagonists |